Last reviewed · How we verify
Nesiritide (Natrecor)
Nesiritide is a recombinant B-type natriuretic peptide that binds to natriuretic peptide receptors, promoting vasodilation and sodium excretion to reduce cardiac preload and afterload.
Nesiritide is a recombinant B-type natriuretic peptide that binds to natriuretic peptide receptors to promote vasodilation, reduce cardiac preload and afterload, and increase sodium excretion. Used for Acute decompensated heart failure with dyspnea at rest or with minimal exertion.
At a glance
| Generic name | Nesiritide (Natrecor) |
|---|---|
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Natriuretic peptide |
| Target | Natriuretic peptide receptor-A (NPR-A) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nesiritide mimics the action of endogenous B-type natriuretic peptide (BNP), a hormone released by the heart in response to increased wall stress. By activating natriuretic peptide receptor-A (NPR-A), it triggers increased cGMP production, leading to smooth muscle relaxation in blood vessels and reduced sodium reabsorption in the kidneys. This results in decreased pulmonary and systemic venous pressure, improved cardiac hemodynamics, and symptomatic relief in acute decompensated heart failure.
Approved indications
- Acute decompensated heart failure with dyspnea at rest or with minimal exertion
Common side effects
- Hypotension
- Headache
- Back pain
- Nausea
- Abdominal pain
- Dizziness
Key clinical trials
- A Study of Ponsegromab in People With Heart Failure (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- Prospective Evaluation of AI-ECG for SHD Detection
- Boston Medical Center Ultrasound Decongestion Study in Heart Failure (NA)
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CM (PHASE3)
- Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
- Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure (NA)
- REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nesiritide (Natrecor) CI brief — competitive landscape report
- Nesiritide (Natrecor) updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI